

Respiratory infections with *Pseudomonas aeruginosa* in children with Cystic Fibrosis; early surveillance and prevention

Submission date
12/09/2005

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
12/09/2005

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
20/09/2010

Condition category
Nutritional, Metabolic, Endocrine

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr G.A. Tramper-Stranders

Contact details

Wilhelmina Kinderziekenhuis

KH.01.419.0

Postbus 85090

Utrecht

Netherlands

3508 AB

+31 (0)30 2504000

g.tramper@umcutrecht.nl

Additional identifiers

Protocol serial number

NTR64

Study information

Scientific Title

Acronym

POPeye-study

Study objectives

Our hypothesis is that the initial infection with *P. aeruginosa* occurs at earlier age than previously reported and that prophylactic treatment of *P. aeruginosa*-negative CF-patients will either prevent or delay the first acquisition of *P. aeruginosa* or eradicate the organism before the onset of persistent colonization and accompanying pulmonary inflammatory response.

Please note that as of 12/09/2008, the sources of funding field was updated. The anticipated end date of this trial was also updated. The previous anticipated end date was 01/11/2008.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Primary study design

Interventional

Study design

Multicentre, randomised, double blinded, placebo controlled, parallel group trial

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Pulmonary *P. aeruginosa* infection, cystic fibrosis

Interventions

Ciprofloxacin 10 mg/kg orally (po) or matching placebo twice daily (bid) and colistin 1 MIU inhalation or matching placebo bid. Three-monthly courses of three weeks, total study duration 3 years.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Early *P. aeruginosa* colonisation as confirmed by:

1. Persistence of *P. aeruginosa* in sputum or oropharyngeal swab culture in two consecutive samples, taken greater than 3 days apart
2. *P. aeruginosa* in one oropharyngeal swab or sputum culture with pulmonary exacerbation

Key secondary outcome(s)

Microbiological:

1. Age at first positive culture
2. Time to *P. aeruginosa* colonisation
3. Respiratory pathogens in culture
4. Resistance pattern of respiratory pathogens

Serological:

5. Seroconversion for anti-pseudomonal antibodies

Clinical:

6. Adverse events
7. Clinical parameters (lung function, body weight and chest radiograph scores, inflammation parameters)
8. Number of pulmonary exacerbations
9. Antimicrobial agent use

Completion date

01/03/2009

Eligibility

Key inclusion criteria

1. CF diagnosis as confirmed by sweat chloride test and/or genotyping
2. Aged less than 18 years old
3. No evidence of *P. aeruginosa* in cultures taken in period 2004 - 2005
4. Antibody titer less than 1:1250 for three antigens of *P. aeruginosa*
5. No regular treatment against *P. aeruginosa*
6. Informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Upper age limit

18 Years

Sex

All

Key exclusion criteria

1. Aged greater than 18 years
2. *P. aeruginosa* in cultures after 2003
3. Participating in another trial

Date of first enrolment

01/07/2005

Date of final enrolment

01/03/2009

Locations

Countries of recruitment

Netherlands

Study participating centre

Wilhelmina Kinderziekenhuis

Utrecht

Netherlands

3508 AB

Sponsor information

Organisation

University Medical Center Utrecht (UMCU) (The Netherlands)

ROR

<https://ror.org/0575yy874>

Funder(s)

Funder type

Research organisation

Funder Name

Added 12/09/2008:

Funder Name

Initial funding was from the investigator for one year (Netherlands)

Funder Name

Dutch Cystic Fibrosis Foundation (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2010		Yes	No